Cagrilintide is an investigational, long-acting synthetic analog of the pancreatic hormone amylin, developed by Novo Nordisk under the early research code AM833, and it is not approved by the FDA or any other major regulator. The published record describes it as a clinical-stage compound given as a once-weekly subcutaneous injection for chronic weight management, studied both on its own and in a fixed-dose combination with semaglutide known as CagriSema. Its central mechanism is to mimic amylin, the natural satiety hormone that pancreatic beta cells release alongside insulin after a meal.
Cagrilintide is an investigational once-weekly amylin analog developed by Novo Nordisk under the research code AM833 for chronic weight management, not approved by the FDA or any other major regulator.
Cagrilintide sits in the class of amylin analogs, also called amylin receptor agonists or amylinomimetics, peptide drugs built to reproduce the appetite-regulating actions of the natural hormone amylin. The literature describes it more precisely as a long-acting, non-selective analog, meaning it activates both amylin receptors and the closely related calcitonin receptor.
Cagrilintide is a long-acting, non-selective amylin analog, a synthetic 37-residue peptide developed by Novo Nordisk that activates both amylin and calcitonin receptors.
Amylin, also called islet amyloid polypeptide or IAPP, is a 37-amino-acid hormone that pancreatic beta cells release together with insulin whenever nutrients arrive after a meal. The published record characterizes it as insulin's satiety and glucose-regulating partner rather than a hormone acting on the same targets, signaling fullness to the hindbrain so meals end sooner.
Amylin is a 37-amino-acid hormone co-secreted with insulin that signals satiety through the area postrema, slows gastric emptying, and suppresses glucagon to flatten the post-meal glucose rise.
Amylin has no single dedicated receptor. Its receptors are assembled when the calcitonin receptor, a G-protein-coupled receptor, pairs with one of three accessory proteins called RAMPs to form the AMY1, AMY2, and AMY3 subtypes, and cagrilintide is described as non-selective because it engages both these amylin receptors and the unmodified calcitonin receptor.
Amylin receptors form when the calcitonin receptor pairs with RAMP1, RAMP2, or RAMP3, and cagrilintide non-selectively activates both these AMY1, AMY2, and AMY3 subtypes and the calcitonin receptor, raising cyclic AMP in area postrema neurons.
The engineering that turns an unstable natural hormone into a once-weekly drug falls into two categories. The centerpiece is acylation, a fatty-acid side chain that binds reversibly to albumin and shields the peptide from rapid clearance, stretching its half-life to roughly seven to nine days in human studies.
A fatty-acid side chain that binds reversibly to albumin, combined with amino-acid substitutions that block amylin's fibril formation, extends cagrilintide's half-life to roughly seven to nine days and supports once-weekly subcutaneous dosing.
Cagrilintide reduces food intake mainly by amplifying the brain's own fullness signaling. Continuous activation of amylin and calcitonin receptors in the area postrema drives a satiety signal to the nucleus tractus solitarius and hypothalamic hunger circuits, so eating produces fullness sooner and portions shrink.
Cagrilintide suppresses appetite by activating hindbrain amylin and calcitonin receptors and delaying gastric emptying, and in combination with semaglutide clinical trials reported average weight reductions reaching roughly twenty percent of body weight.
Cagrilintide is an investigational drug with no FDA approval, and as an independent product it has not been approved by any other major regulator for any indication. Its most visible late-stage testing sits in the CagriSema combination, evaluated in large phase 3 obesity and diabetes trials, while the standalone agent has been studied in earlier and mid-stage work.
Cagrilintide is an investigational compound with no FDA approval and no approval as a standalone product from any major regulator, available lawfully only within authorized clinical trials or defined research settings.
The clearest difference is the hormone each drug imitates. Cagrilintide copies amylin and acts on amylin and calcitonin receptors, while semaglutide and other GLP-1 receptor agonists copy glucagon-like peptide-1 and act on the GLP-1 receptor, and because the two appetite pathways are distinct rather than redundant they are being combined rather than swapped.
| Criteria | Cagrilintide | GLP-1 agonists (semaglutide) |
|---|---|---|
| Hormone mimicked | Amylin | Glucagon-like peptide-1 |
| Receptor target | Amylin and calcitonin receptors | GLP-1 receptor |
| Glucose action | Indirect, via slowed emptying and glucagon suppression | Direct, glucose-dependent insulin secretion |
| Approval status | Investigational | Approved for type 2 diabetes and weight management |
| Shared tolerability | Dose-dependent nausea, reduced appetite | Dose-dependent nausea, reduced appetite |
Cagrilintide mimics amylin and acts on amylin and calcitonin receptors while semaglutide mimics GLP-1 and acts on the GLP-1 receptor, and their distinct but converging appetite pathways are the reason the two are combined in CagriSema rather than used interchangeably.
Cagrilintide reproduces two of amylin's classic peripheral actions: it slows the stomach's release of food into the small intestine and it dampens post-meal glucagon secretion. Both effects flatten the post-meal glucose curve, and the same slowed emptying is closely tied to the nausea and early fullness reported with this drug class, especially during dose escalation.
Cagrilintide slows gastric emptying and suppresses post-meal glucagon to flatten the post-meal glucose curve, and that same delayed emptying, combined with direct action on the area postrema, drives the nausea commonly reported during dose escalation.
Educational use only. This article describes what the published scientific and clinical literature reports about Cagrilintide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
